Triple negative breast cancer is a type of breast cancer that lacks three hormone receptors that are commonly targeted in breast cancer treatment: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This subtype of breast cancer is typically more aggressive, harder to treat, and has a poorer prognosis compared to other types of breast cancer. Research in the area of triple negative breast cancer focuses on finding new treatment options, improving survival rates, and understanding the underlying biology of this specific subtype. This research often involves identifying new biomarkers, developing targeted therapies, and exploring the role of immunotherapy in treating triple negative breast cancer.